Your browser doesn't support javascript.
loading
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
Schäfer, Laura; Thom, Nina.
Afiliação
  • Schäfer L; Clinic for Small Animals, Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
  • Thom N; Clinic for Small Animals, Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
Vet Dermatol ; 35(4): 408-417, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38465482
ABSTRACT

BACKGROUND:

Supplementation of polyunsaturated fatty acids (PUFA) enables dose reduction of prednisolone and ciclosporin in canine atopic dermatitis (cAD).

OBJECTIVE:

To determine if oral administration of PUFA reduces the dose of oclacitinib in cAD. ANIMALS Twenty-two client-owned dogs with cAD receiving oclacitinib. MATERIALS AND

METHODS:

Dogs received a fish oil product (PUFA) or paraffin oil (placebo) for 16 weeks. Owners adjusted the oclacitinib dose according to daily pruritus assessments. On Day (D)0, D56 and D112, Canine Atopic Dermatitis Extent and Severity Index, fourth iteration (CADESI-04), pruritus Visual Analog Scale (PVAS), quality-of-life score (QoL), Global Assessment (GA), quality-of-coat (QoC) and adverse events were recorded.

RESULTS:

Mean daily oclacitinib dose was significantly reduced in the PUFA group from 0.51 ± 0.20 mg/kg/24 h (D0) to 0.19 ± 0.14 mg/kg/24 h (D85-112; p < 0.00001) and not in the placebo group (D0 0.70 ± 0.33 mg/kg/24 h; D85-112 0.53 ± 0.35 mg/kg/24 h, p = 0.5422). CADESI-04 did not change over time or differ between groups. PVAS was significantly lower in the PUFA group (2.8 ± 1.5) compared to placebo (4.2 ± 1.6) at D112 (p = 0.0375). QoL and QoC improved only in the PUFA group (QoL D0 20 ± 7, D112 12 ± 5, p = 0.0057; QoC D0 0 ± 0.5, D112 1 ± 0.5, p = 0.0410). GA on D112 was higher in the PUFA group (p = 0.008). No adverse events were observed.

CONCLUSION:

Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Dermatite Atópica / Doenças do Cão Idioma: En Revista: Vet Dermatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Dermatite Atópica / Doenças do Cão Idioma: En Revista: Vet Dermatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha